Zurzuvae (zuranolone) - Biogen, Supernus Pharma
Profiling zuranolone as a treatment option for postpartum depression. (PubMed, Expert Rev Neurother) - Sep 18, 2026 - "However, evidence for long-term outcomes is limited due to the lack of comparative trials with other active treatments for postpartum depression and the exclusion of lactating populations or those with psychiatric comorbidities. More studies are needed to define the full scope of its clinical applicability." 
Journal • Review • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
http://www.ncbi.nlm.nih.gov/pubmed/42750260
 
Christina González-Torres; Verinder Sharma
 
Sep 18, 2026
 
Prev Next